- Home
- DFP vs PACB Comparison
DFP vs PACB Comparison
Compare DFP & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFP
- PACB
- Stock Information
- Founded
- DFP 2013
- PACB 2000
- Country
- DFP United States
- PACB United States
- Employees
- DFP N/A
- PACB N/A
- Industry
- DFP Investment Managers
- PACB Biotechnology: Laboratory Analytical Instruments
- Sector
- DFP Finance
- PACB Industrials
- Exchange
- DFP Nasdaq
- PACB Nasdaq
- Market Cap
- DFP 396.2M
- PACB 364.2M
- IPO Year
- DFP N/A
- PACB 2010
- Fundamental
- Price
- DFP $20.01
- PACB $0.96
- Analyst Decision
- DFP
- PACB Buy
- Analyst Count
- DFP 0
- PACB 9
- Target Price
- DFP N/A
- PACB $2.34
- AVG Volume (30 Days)
- DFP 56.2K
- PACB 9.9M
- Earning Date
- DFP 01-01-0001
- PACB 05-08-2025
- Dividend Yield
- DFP 6.73%
- PACB N/A
- EPS Growth
- DFP N/A
- PACB N/A
- EPS
- DFP N/A
- PACB N/A
- Revenue
- DFP N/A
- PACB $152,357,000.00
- Revenue This Year
- DFP N/A
- PACB $4.67
- Revenue Next Year
- DFP N/A
- PACB $19.09
- P/E Ratio
- DFP N/A
- PACB N/A
- Revenue Growth
- DFP N/A
- PACB N/A
- 52 Week Low
- DFP $15.45
- PACB $0.85
- 52 Week High
- DFP $19.31
- PACB $2.72
- Technical
- Relative Strength Index (RSI)
- DFP 50.82
- PACB 41.28
- Support Level
- DFP $19.85
- PACB $0.85
- Resistance Level
- DFP $20.19
- PACB $1.15
- Average True Range (ATR)
- DFP 0.20
- PACB 0.09
- MACD
- DFP -0.04
- PACB 0.00
- Stochastic Oscillator
- DFP 40.00
- PACB 34.45
About DFP Flaherty & Crumrine Dynamic Preferred and Income Fund Inc.
Flaherty & Crumrine Dynamic Preferred and Income Fund Inc is a diversified, closed-end management investment company. Its investment objective is to seek total return, with an emphasis on high current income.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.